This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Henderson, B. W. Articles by Oseroff, A. R. Search for Related Content PubMed PubMed Citation Articles by Henderson, B. W. Articles by Oseroff, A. R.

Photofrin Photodynamic Therapy Can Significantly Deplete or Preserve Oxygenation in Human Basal Cell Carcinomas during Treatment, Depending on Fluence Rate¹

Photodynamic Therapy Center [B. W. H., T. M. B., L. A. V., D. A. B., M. T. C.], Department of Dermatology [N. P. F., D. B., T. A. S., J. D. Z., A. S. D., A. R. O.] and Biomathematics/Biostatistics Resource [W. R. G.], Roswell Park Cancer Institute, Buffalo, New York 14263

At high fluence rates in animal models, photodynamic therapy (PDT) can photochemically deplete ambient tumor oxygen through the generation of singlet oxygen, causing acute hypoxia and limiting treatment effectiveness. We report that standard clinical treatment conditions (1 mg/kg Photofrin, light at 630 nm and 150 mW/cm²), which are highly effective for treating human basal cell carcinomas, significantly diminished tumor oxygen levels during initial light delivery in a majority of carcinomas. Oxygen depletion could be found during at least 40% of the total light dose, but tumors appeared well oxygenated toward the end of treatment. In contrast, initial light delivery at a lower fluence rate of 30 mW/cm² increased tumor oxygenation in a majority of carcinomas. Laser treatment caused an intensity- and treatment time-dependent increase in tumor temperature. The data suggest that high fluence rate treatment, although effective, may be inefficient.

This article has been cited by other articles:

				W. J. Cottrell, A. D. Paquette, K. R. Keymel, T. H. Foster, and A. R. Oseroff Irradiance-Dependent Photobleaching and Pain in {delta}-Aminolevulinic Acid-Photodynamic Therapy of Superficial Basal Cell Carcinomas Clin. Cancer Res., July 15, 2008; 14(14): 4475 - 4483. [Abstract] [Full Text] [PDF]

				M. Seshadri, D. A. Bellnier, L. A. Vaughan, J. A. Spernyak, R. Mazurchuk, T. H. Foster, and B. W. Henderson Light Delivery over Extended Time Periods Enhances the Effectiveness of Photodynamic Therapy Clin. Cancer Res., May 1, 2008; 14(9): 2796 - 2805. [Abstract] [Full Text] [PDF]

				Z. Xiao, S. Halls, D. Dickey, J. Tulip, and R. B. Moore Fractionated versus Standard Continuous Light Delivery in Interstitial Photodynamic Therapy of Dunning Prostate Carcinomas Clin. Cancer Res., December 15, 2007; 13(24): 7496 - 7505. [Abstract] [Full Text] [PDF]

				B. W. Henderson, C. Daroqui, E. Tracy, L. A. Vaughan, G. M. Loewen, M. T. Cooper, and H. Baumann Cross-Linking of Signal Transducer and Activator of Transcription 3--A Molecular Marker for the Photodynamic Reaction in Cells and Tumors Clin. Cancer Res., June 1, 2007; 13(11): 3156 - 3163. [Abstract] [Full Text] [PDF]

				T. Maisch, J. Baier, B. Franz, M. Maier, M. Landthaler, R.-M. Szeimies, and W. Baumler The role of singlet oxygen and oxygen concentration in photodynamic inactivation of bacteria PNAS, April 24, 2007; 104(17): 7223 - 7228. [Abstract] [Full Text] [PDF]

				S. M. Hahn, M. E. Putt, J. Metz, D. B. Shin, E. Rickter, C. Menon, D. Smith, E. Glatstein, D. L. Fraker, and T. M. Busch Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin. Cancer Res., September 15, 2006; 12(18): 5464 - 5470. [Abstract] [Full Text] [PDF]

				N. Solban, S. K. Pal, S. K. Alok, C. K. Sung, and T. Hasan Mechanistic Investigation and Implications of Photodynamic Therapy Induction of Vascular Endothelial Growth Factor in Prostate Cancer Cancer Res., June 1, 2006; 66(11): 5633 - 5640. [Abstract] [Full Text] [PDF]

				A. R. Oseroff, S. Shieh, N. P. Frawley, R. Cheney, L. E. Blumenson, E. K. Pivnick, and D. A. Bellnier Treatment of Diffuse Basal Cell Carcinomas and Basaloid Follicular Hamartomas in Nevoid Basal Cell Carcinoma Syndrome by Wide-Area 5-Aminolevulinic Acid Photodynamic Therapy Arch Dermatol, January 1, 2005; 141(1): 60 - 67. [Abstract] [Full Text] [PDF]

				H.-W. Wang, M. E. Putt, M. J. Emanuele, D. B. Shin, E. Glatstein, A. G. Yodh, and T. M. Busch Treatment-Induced Changes in Tumor Oxygenation Predict Photodynamic Therapy Outcome Cancer Res., October 15, 2004; 64(20): 7553 - 7561. [Abstract] [Full Text] [PDF]

				T. M. Busch, S. M. Hahn, E. P. Wileyto, C. J. Koch, D. L. Fraker, P. Zhang, M. Putt, K. Gleason, D. B. Shin, M. J. Emanuele, et al. Hypoxia and Photofrin Uptake in the Intraperitoneal Carcinomatosis and Sarcomatosis of Photodynamic Therapy Patients Clin. Cancer Res., July 15, 2004; 10(14): 4630 - 4638. [Abstract] [Full Text] [PDF]

				B. W. Henderson, S. O. Gollnick, J. W. Snyder, T. M. Busch, P. C. Kousis, R. T. Cheney, and J. Morgan Choice of Oxygen-Conserving Treatment Regimen Determines the Inflammatory Response and Outcome of Photodynamic Therapy of Tumors Cancer Res., March 15, 2004; 64(6): 2120 - 2126. [Abstract] [Full Text] [PDF]

				J. W. Snyder, W. R. Greco, D. A. Bellnier, L. Vaughan, and B. W. Henderson Photodynamic Therapy: A Means to Enhanced Drug Delivery to Tumors Cancer Res., December 1, 2003; 63(23): 8126 - 8131. [Abstract] [Full Text] [PDF]

				T.-W. Wong, E. Tracy, A. R Oseroff, and H. Baumann Photodynamic Therapy Mediates Immediate Loss of Cellular Responsiveness to Cytokines and Growth Factors Cancer Res., July 1, 2003; 63(13): 3812 - 3818. [Abstract] [Full Text] [PDF]

				B. W. Pogue, J. A. O'Hara, E. Demidenko, C. M. Wilmot, I. A. Goodwin, B. Chen, H. M. Swartz, and T. Hasan Photodynamic Therapy with Verteporfin in the Radiation-induced Fibrosarcoma-1 Tumor Causes Enhanced Radiation Sensitivity Cancer Res., March 1, 2003; 63(5): 1025 - 1033. [Abstract] [Full Text] [PDF]